Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
recombinant human Angiostatin protein · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| recombinant human Angiostatin protein | DRUG | - |
| paclitaxel | DRUG | - |
| carboplatin | DRUG | - |
Inclusion: * Histological or cytological confirmed Stage IIIB NSCLC with malignant pleural effusions, or Stage IV NSCLC or recurrent NSCLC * No previous chemotherapy for NSCLC * Have one lesion that is bidimensionally measurable by physical exam, MRI, or CT greater than 1 cm in diameter * Specified...
Recombinant human Angiostatin protein is being studied for use in non-small-cell lung cancer. It is an investigational therapy that was evaluated in a Phase 2 clinical trial in combination with paclitaxel and carboplatin for patients with this condition. The trial has been completed.
Recombinant human Angiostatin protein targets angiogenesis, the process of new blood vessel formation that tumors rely on for growth. By inhibiting this process, the drug aims to cut off the blood supply to the tumor. It is being studied in non-small-cell lung cancer.
CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is developing recombinant human Angiostatin protein. The company is conducting clinical research on this investigational therapy for non-small-cell lung cancer.
Recombinant human Angiostatin protein is in Phase 2 clinical development. It has completed a Phase 2 trial in non-small-cell lung cancer. The drug is investigational and has not been approved by the FDA.
Recombinant human Angiostatin protein has one completed clinical trial, NCT00049790. This Phase 2 study evaluated the safety and efficacy of rhAngiostatin administered in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer. The trial was conducted in the United States.
Yes, recombinant human Angiostatin protein is also known as rhAngiostatin. The clinical trial NCT00049790 uses the name rhAngiostatin to refer to this investigational drug being studied for non-small-cell lung cancer.